참고문헌
- Horwitz ME. Stem-cell transplantation for inherited immunodeficiency disorders. Pediatr Clin North Am 2000;47(6):171-87. https://doi.org/10.1016/S0031-3955(05)70200-5
- Patzer L, Kentouche K, Ringelmann F, Misselwitz J. Renal function following hematological stem cell transplantation in childhood. Pediatr Nephrol 2003;18(7):623-35. https://doi.org/10.1007/s00467-003-1146-9
- Baird K, Cooke K, Schultx KR. Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am 2010;57(1):297-322. https://doi.org/10.1016/j.pcl.2009.11.003
- Cheuk DK, Wang P, Lee TL, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant 2007;40(10):935-44. https://doi.org/10.1038/sj.bmt.1705835
- Jacobsohn DA. Acute graft-versus-host disease in children. Bone Marrow Transplant 2008;41(2):215-21. https://doi.org/10.1038/sj.bmt.1705885
- Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993;24(6):472-95. https://doi.org/10.2165/00003088-199324060-00004
- Del Mar Fernandez De Gatta M. Immunosuppressive therapy for pediatric transplant patients: Pharmacokinetic considerations. Clin Pharmacokinet 2002;41(2):115-35. https://doi.org/10.2165/00003088-200241020-00004
- Dupuis LL, Taylor T, Saunders EF. Disposition of two oral formulation of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants. Pharmacotherapy 2006;26(1):15-22. https://doi.org/10.1592/phco.2006.26.1.15
- Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise consensus conference on cyclosporine monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995;17(6):642-54. https://doi.org/10.1097/00007691-199512000-00017
- Belitsky P, Dunn S, Johnston A, Levy G. Impact of absorption profiling on efficacy and safety of cyclosporine therapy in transplant recipients. Clin Pharmacokinet 2000;39(2):117-25. https://doi.org/10.2165/00003088-200039020-00003
- Pal Falck. A population pharmacokinetic model of cyclosporin applicable for assisting dose management of kidney transplant recipients. Clin pharmacokinet 2009;48(9):615-23. https://doi.org/10.2165/11313380-000000000-00000
- Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM. Ther Drug Moni 2004;26(1):23-30. https://doi.org/10.1097/00007691-200402000-00006
- Sun B, Li XY, Gao JW, et al. Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplantation recipients. Ther Drug monit 2010;32(6):715-22. https://doi.org/10.1097/FTD.0b013e3181fb6ce3
- Fanta S, Jonsson S, Backman JT, Karlsson M.O, Hoppu K. Developmental pharmacokinetics of ciclosporin-a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol 2007;64(6):772-84. https://doi.org/10.1111/j.1365-2125.2007.03003.x
- Irtan S, Saint-Marcoux F, Rousseau A, et al. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit 2007;29:96-102. https://doi.org/10.1097/FTD.0b013e3180310f9d
- Willemze AJ, Cremers SC, Schoemaker RC, et al. Ciclosporin kinetics in children after stem cell transplantation. Br J Clin Pharmacol 2008;66(4):539-45. https://doi.org/10.1111/j.1365-2125.2008.03217.x
- Jacobson PA, Ng J, Green KG, et al. Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. Bio Blood Marrow Transplantation 2003;9(5): 304-11. https://doi.org/10.1016/S1083-8791(03)00076-4
- Kim SH, Kim KI, Yun HY, et al. Population pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation in leukemic patients. Korean J Clin Pharm 2010;20(1):9-16.